Compass Therapeutics (CMPX) Research & Development (2019 - 2026)

Compass Therapeutics (CMPX) has 8 years of Research & Development data on file, last reported at $13.4 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 2.57% year-over-year to $13.4 million; the trailing twelve-month figure through Mar 2026 stood at $56.3 million (up 22.72% YoY), and the FY2025 full-year result was $56.0 million, up 32.18% from the prior year.
• Research & Development fell to $13.4 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.4 million in Q2 2025 to a low of $4.4 million in Q1 2022.
• A 5-year average of $10.6 million and a median of $10.2 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 210.43% in 2022 and retreated 9.8% in 2023, its largest moves.
• Tracing CMPX's Research & Development over 5 years: stood at $9.9 million in 2022, then climbed by 25.16% to $12.4 million in 2023, then climbed by 4.93% to $13.0 million in 2024, then rose by 4.86% to $13.7 million in 2025, then fell by 2.06% to $13.4 million in 2026.
• Business Quant data shows CMPX's Research & Development at $13.4 million in Q1 2026, $13.7 million in Q4 2025, and $12.8 million in Q3 2025.